| Dr Jacquelyn Davis Niedringhaus, AUD | |
|
1169 Ebenezer Rd, Rock Hill, SC 29732-2364 | |
| (803) 327-1900 | |
| (803) 327-4146 |
| Full Name | Dr Jacquelyn Davis Niedringhaus |
|---|---|
| Gender | Female |
| Speciality | Qualified Audiologist |
| Experience | 24 Years |
| Location | 1169 Ebenezer Rd, Rock Hill, South Carolina |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1376500561 | NPI | - | NPPES |
| SA0017 | Medicaid | SC | |
| GP1087 | Medicaid | SC |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 231H00000X | Audiologist | 457 (South Carolina) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Audiology Center, Inc. | 5991871105 | 2 |
News Archive
Elderly patients who use antipsychotic drugs have a 60 percent increased risk of developing pneumonia compared to non-users.
As both cost containment of care and services and treatment-as-prevention gain greater prominence in the global fight against HIV/AIDS during the Vienna AIDS Conference, AIDS Healthcare Foundation (AHF), which currently provides AIDS medical care to more than 139,000 individuals in 23 countries worldwide, will host a satellite session today, July 21st, titled "Test and Treat: Getting to 10 Million on ARVs" (IAC Mini Room #5 at 6:30pm) preceded by a press conference (5pm, Media Center, Room PCR #2).
Boehringer Ingelheim Pharmaceuticals, Inc. today reported preliminary results from the randomized Phase II part of a Phase I/II study involving the company's investigational compound volasertib in newly diagnosed patients with acute myeloid leukemia (AML) considered ineligible for intensive remission induction therapy.
A new study published on the preprint server bioRxiv* aimed to investigate the impacts of COVID-19 on people with various illnesses. Specifically, the researchers at the Rockefeller Cancer Institute, and the University of Arkansas for Medical Sciences wanted to see the effects of COVID-19 on patients with cancer and other infectious diseases.
Clinical trials using patients' own immune cells to target tumors have yielded promising results. However, this approach usually works only if the patients also receive large doses of drugs designed to help immune cells multiply rapidly, and those drugs have life-threatening side effects. Now a team of MIT engineers has devised a way to deliver the necessary drugs by smuggling them on the backs of the cells sent in to fight the tumor. That way, the drugs reach only their intended targets, greatly reducing the risk to the patient.
› Verified 6 days ago
| Provider Name | Audiology Center, Inc. |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1669663613 PECOS PAC ID: 5991871105 Enrollment ID: O20080911000202 |
News Archive
Elderly patients who use antipsychotic drugs have a 60 percent increased risk of developing pneumonia compared to non-users.
As both cost containment of care and services and treatment-as-prevention gain greater prominence in the global fight against HIV/AIDS during the Vienna AIDS Conference, AIDS Healthcare Foundation (AHF), which currently provides AIDS medical care to more than 139,000 individuals in 23 countries worldwide, will host a satellite session today, July 21st, titled "Test and Treat: Getting to 10 Million on ARVs" (IAC Mini Room #5 at 6:30pm) preceded by a press conference (5pm, Media Center, Room PCR #2).
Boehringer Ingelheim Pharmaceuticals, Inc. today reported preliminary results from the randomized Phase II part of a Phase I/II study involving the company's investigational compound volasertib in newly diagnosed patients with acute myeloid leukemia (AML) considered ineligible for intensive remission induction therapy.
A new study published on the preprint server bioRxiv* aimed to investigate the impacts of COVID-19 on people with various illnesses. Specifically, the researchers at the Rockefeller Cancer Institute, and the University of Arkansas for Medical Sciences wanted to see the effects of COVID-19 on patients with cancer and other infectious diseases.
Clinical trials using patients' own immune cells to target tumors have yielded promising results. However, this approach usually works only if the patients also receive large doses of drugs designed to help immune cells multiply rapidly, and those drugs have life-threatening side effects. Now a team of MIT engineers has devised a way to deliver the necessary drugs by smuggling them on the backs of the cells sent in to fight the tumor. That way, the drugs reach only their intended targets, greatly reducing the risk to the patient.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Jacquelyn Davis Niedringhaus, AUD 1364 Ebenezer Rd, Rock Hill, SC 29732-2337 Ph: (803) 327-1900 | Dr Jacquelyn Davis Niedringhaus, AUD 1169 Ebenezer Rd, Rock Hill, SC 29732-2364 Ph: (803) 327-1900 |
News Archive
Elderly patients who use antipsychotic drugs have a 60 percent increased risk of developing pneumonia compared to non-users.
As both cost containment of care and services and treatment-as-prevention gain greater prominence in the global fight against HIV/AIDS during the Vienna AIDS Conference, AIDS Healthcare Foundation (AHF), which currently provides AIDS medical care to more than 139,000 individuals in 23 countries worldwide, will host a satellite session today, July 21st, titled "Test and Treat: Getting to 10 Million on ARVs" (IAC Mini Room #5 at 6:30pm) preceded by a press conference (5pm, Media Center, Room PCR #2).
Boehringer Ingelheim Pharmaceuticals, Inc. today reported preliminary results from the randomized Phase II part of a Phase I/II study involving the company's investigational compound volasertib in newly diagnosed patients with acute myeloid leukemia (AML) considered ineligible for intensive remission induction therapy.
A new study published on the preprint server bioRxiv* aimed to investigate the impacts of COVID-19 on people with various illnesses. Specifically, the researchers at the Rockefeller Cancer Institute, and the University of Arkansas for Medical Sciences wanted to see the effects of COVID-19 on patients with cancer and other infectious diseases.
Clinical trials using patients' own immune cells to target tumors have yielded promising results. However, this approach usually works only if the patients also receive large doses of drugs designed to help immune cells multiply rapidly, and those drugs have life-threatening side effects. Now a team of MIT engineers has devised a way to deliver the necessary drugs by smuggling them on the backs of the cells sent in to fight the tumor. That way, the drugs reach only their intended targets, greatly reducing the risk to the patient.
› Verified 6 days ago
Dr. Amanda Patterson Scobey, AU.D. Audiologist Medicare: Not Enrolled in Medicare Practice Location: 1565 Ebenezer Rd, Suite 110, Rock Hill, SC 29732 Phone: 803-327-4000 Fax: 803-366-9829 | |
Dr. Robyn Adele Bogan, AU.D. Audiologist Medicare: Accepting Medicare Assignments Practice Location: 200 S Herlong Ave Ste A, Rock Hill, SC 29732 Phone: 803-328-1864 Fax: 803-328-1865 | |
Kim Thien Nguyen Ho, AU.D. Audiologist Medicare: Accepting Medicare Assignments Practice Location: 200 S Herlong Ave, Suite A, Rock Hill, SC 29732 Phone: 803-328-1864 Fax: 803-328-1865 | |
Dr. Sarah Elizabeth Vair, AUD Audiologist Medicare: Accepting Medicare Assignments Practice Location: 200 S Herlong Ave, Suite A, Rock Hill, SC 29732 Phone: 803-328-1864 Fax: 803-328-1865 | |
Dr. Kayla Cathleen Newkirk, AU.D Audiologist Medicare: Accepting Medicare Assignments Practice Location: 200 S Herlong Ave Ste A, Rock Hill, SC 29732 Phone: 803-328-1864 | |
Dr. Sarah Gunning, AUD Audiologist Medicare: Not Enrolled in Medicare Practice Location: 197 Piedmont Blvd Ste 110, Rock Hill, SC 29732 Phone: 803-805-7290 |